Combining PD-1/PD-L1 and CTLA-4 inhibitors for the treatment of colorectal cancer: A systematic review and meta-analysis
DOI:
https://doi.org/10.54097/0shjns21Keywords:
Immunotherapy; CTLA-4; PD-1/PD-L1; meta-analysis; colorectal cancer.Abstract
Objective: The objective of this study is to evaluate the effectiveness of employing both PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer, with a specific emphasis on colorectal cancer (CRC). Approaches: A methodical search of internet databases was performed to discover pertinent studies. The eligible studies included those that examined the management for those had colorectal cancer with the combined medications. Afterwards, the pertinent indicators were computed. Results: Eight publications were included in the study, and they provided data on the objective response rate, disease control rate, progression-free survival rate, and overall survival rate. The reported rates were 64.6%, 82.68%, 64.60%, and 73.11%, respectively. Conclusion: The findings of this investigation suggest that using both PD-1/PD-L1 and CTLA-4 inhibitors together is of great development potential when treating CRC with mismatch repair errors. Additionally, the treatment-related side effects are manageable.
Downloads
References
M. Kreidieh, D. Mukherji, S. Temraz, A. Shamseddine. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. Biomed Res Int, 2020, 2020:9037217.
F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, and A. Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6):394-424.
R.L. Siegel, K.D. Miller, S.A. Fedewa, D.J. Ahnen, R.G.S. Meester, A. Barzi, A. Jemal. Colorectal cancer statistics, 2017. CA Cancer J Clin, 2017, 67(3):177-193.
L.A.E. Hughes, C. Simons, P.A. van den Brandt, M. van Engeland, M.P. Weijenberg. Lifestyle, Diet, and Colorectal Cancer Risk According to (Epi) genetic Instability: Current Evidence and Future Directions of Molecular Pathological Epidemiology. Curr Colorectal Cancer Rep, 2017, 13(6):455-469.
D. Romero. New first-line therapy for dMMR/MSI-H CRC. Nat Rev Clin Oncol, 2021, 18(2):63.
S. Emambux, G. Tachon, A. Junca, D. Tougeron. Results and challenges of immune checkpoint inhibitors in colorectal cancer. Expert Opin Biol Ther, 2018, 18(5):561-573.
Q. Gou, C. Dong, H. Xu, B. Khan, J. Jin, Q. Liu, J. Shi, Y. Hou. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis, 2020, 11(11):955.
R.J. Walsh, R. Sundar, J.S.J. Lim. Immune checkpoint inhibitor combinations-current and emerging strategies. Br J Cancer, 2023, 128(8):1415-1417.
D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 2009, 6(7):e1000097.
H. Yao, X. Chen, X. Tan. Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients. BMC Cancer, 2021, 21(1):449.
M.J. Overman, S. Lonardi, K.Y.M. Wong, H.J. Lenz, F. Gelsomino, M. Aglietta, M.A. Morse, E. Van Cutsem, R. McDermott, A. Hill, M.B. Sawyer, A. Hendlisz, B. Neyns, M. Svrcek, R.A. Moss, J.M. Ledeine, Z.A. Cao, S. Kamble, S. Kopetz, T. André. Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol, 2018, 36(8):773-779.
H.J. Lenz, E. Van Cutsem, M. Luisa Limon, K.Y.M. Wong, A. Hendlisz, M. Aglietta, P. García-Alfonso, B. Neyns, G. Luppi, D.B. Cardin, T. Dragovich, U. Shah, S. Abdullaev, J. Gricar, J.M. Ledeine, M.J. Overman, S. Lonardi. First-Line Nivolumab plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol, 2022, 40(2):161-170.
M.J. Overman, H.-J. Lenz, T. Andre, M. Aglietta, M.K. Wong, G. Luppi, E. Van Cutsem, R.S. McDermott, A. Hendlisz, D.B. Cardin, M. Morse, B. Neyns, A.G. Hill, M.L. Limon, P. Garcia-Alfonso, A. Krishnamurthy, F. Chen, S. Abdullaev, S. Soleymani, S. Lonardi. Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142. Journal of Clinical Oncology, 2022, 40(16_suppl):3510-3510.
T. André, S. Lonardi, K.Y.M. Wong, H.J. Lenz, F. Gelsomino, M. Aglietta, M.A. Morse, E. Van Cutsem, R. McDermott, A. Hill, M.B. Sawyer, A. Hendlisz, B. Neyns, S. Abdullaev, A. Memaj, M. Lei, M. Dixon, S. Kopetz, M.J. Overman. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol, 2022, 33(10):1052-1060.
T. Andre, E. Elez, E. Van Cutsem, L.H. Jensen, J. Bennouna, G. Mendez, M. Schenker, C. De La Fouchardiere, M.L. Limon, T. Yoshino, J. Li, H.-J. Lenz, J.L. Manzano Mozo, G. Tortora, R. Garcia-Carbonero, E. Cela, Y. Yang, M. Lei, L. Jin, S. Lonardi. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. Journal of Clinical Oncology, 2024, 42(3_suppl):LBA768-LBA768.
P. Manca, F. Corti, R. Intini, G. Mazzoli, R. Miceli, M.M. Germani, F. Bergamo, M. Ambrosini, E. Cristarella, R. Cerantola, C. Boccaccio, G. Ricagno, F. Ghelardi, G. Randon, G. Leoncini, M. Milione, M. Fassan, C. Cremolini, S. Lonardi, F. Pietrantonio. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Eur J Cancer, 2023, 187:15-24.
E.X. Chen, D.J. Jonker, J.M. Loree, H.F. Kennecke, S.R. Berry, F. Couture, C.E. Ahmad, J.R. Goffin, P. Kavan, M. Harb, B. Colwell, S. Samimi, B. Samson, T. Abbas, N. Aucoin, F. Aubin, S.L. Koski, A.C. Wei, N.M. Magoski, D. Tu, C.J. O'Callaghan. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients with Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. JAMA Oncol, 2020, 6(6):831-838.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
